Table 1 Characteristics of uveitis in patients with UG and OHT-SU.
From: Prevalence and clinical characteristics of uveitic glaucoma: multicentric study in Bogotá, Colombia
Clinical characteristics | UG N = 108 (%) | OHT-SU N = 83 (%) | P-valuea |
|---|---|---|---|
Sex: Female/Male: | 62 (57.40%)/46 (42.59%) | 48 (57.83%)/35 (42.16%) | 0.953 |
Ethnicity: | |||
Latino | 106 (98.14%) | 83 (100%) | 0.51 |
Asian | 1 (0.93%) | - | |
European | 1 (0.93%) | - | |
Bilateral compromise | 45 (41,66%) | 44 (53.01%) | 0.119 |
Age of first uveitis episode mean (IQR 25th and 75th): | 49.0 (33.0– 65.0) | 46.0 (31.0–60.0) | 0.379 |
Follow-up time in weeks | 169.1 (SD 189.3) | 107.4 (SD 156.7) | 0.070 |
Age > 60 years | 37 (34.25%) | 26 (31.32%) | 0.497 |
Bilateral compromise | 45 (41.66%) | 44 (53.01%) | 0.119 |
Type of inflammation | |||
Granulomatous | 16 (14.81%) | 9 (10.84%) | 0.399 |
Non-granulomatous | 88 (81.48%) | 72 (86.74%) | |
Missing data | 4 (3.70%) | 2 (2.40%) | |
Anatomic Localisation | |||
Anterior | 57 (52.57%) | 46 (55.42%) | 0.126 |
Anterior + Intermediate | 1 (0.92%) | 0 (0%) | |
Intermediate | 3 (2.77%) | 8 (9.63%) | |
Posterior | 6 (5.55%) | 1 (1.20%) | |
Panuveitis | 38 (35.18%) | 27 (32.53%) | |
Missing data | 3 (2.77%) | 1 (1.20%) | |
Course: | |||
Acute | 14 (12.96%) | 11(13.25%) | 0.558 |
Chronic | 40 (37.03%) | 36 (43.37%) | |
Recurrent | 54 (50.0%) | 35 (42.16%) | |
Missing data | 0 (0%) | 1 (1.20%) | |
Aetiology | |||
Autoimmune | 13 (12.03%) | 13 (15.66%) | 0.933 |
Autoinflammatory | 39 (36.11%) | 28 (33.73%) | |
Infectious | 20 (18.51%) | 17 (20.48%) | |
Mixed | 8 (7.40%) | 6 (7.22%) | |
Others | 27 (25.0%) | 18 (21.6%) | |
Missing data | 1 (0.92%) | 1 (1.20%) | |
Worst anterior chamber cellularity: | |||
0+ | 35 (32.40%) | 23 (27.71%) | 0.623 |
0.5+ | 14 (12.96%) | 16 (19.27%) | |
1+ | 19 (17.59%) | 12 (14.45%) | |
2+ | 19 (17.59%) | 13 (15.66%) | |
3+ | 13 (12.03%) | 12 (14.45%) | |
4+ | 6 (5.55%) | 6 (7.22%) | |
Missing data | 2 (1.85%) | 1 (1.20%) | |
Worst anterior chamber flare: | |||
0+ | 89 (82.40%) | 66 (79.51%) | 0.664 |
0.5+ | 2 (1.85%) | 3 (3.61%) | |
1+ | 9 (8.33%) | 6 (7.22%) | |
2+ | 0 (0%) | 5 (6.02%) | |
3+ | 2 (1.85%) | 0 (0%) | |
4+ | 4 (3.70%) | 2 (2.40%) | |
Missing data | 2 (1.85%) | 1 (1.20%) | |
Worst vitreous cellularity: | |||
0+ | 73 (67.59%) | 42 (50.60%) | 0.074 |
0.5+ | 6 (5.55%) | 12 (14.45%) | |
1+ | 8 (7.40%) | 9 (10.84%) | |
2+ | 10 (9.25%) | 6 (7.22%) | |
3+ | 3 (2.77%) | 5 (6.02%) | |
4+ | 1 (0.92%) | 0 (0%) | |
Missing data | 7 (6.48%) | 9 (10.84%) | |
Worst vitreous haze: | |||
0+ | 74 (68.51%) | 51 (61.44%) | 0.658 |
0.5+ | 1 (0.92%) | 4 (4.81%) | |
1+ | 10 (9.25%) | 5 (6.02%) | |
2+ | 9 (8.33%) | 9 (10.84%) | |
3+ | 4 (3.70%) | 2 (2.40%) | |
4+ | 5 (4.62%) | 4 (4.81%) | |
Missing data | 5 (4.62%) | 8 (9.63%) | |
Final visual acuity (LogMAR): | 0.3 (0.0–1.0) | 0.3 (0.0–1.3) | 0.380 |
Hypopyon | 2 (1.85%) | 1 (1.20%) | 0.721 |
Cataract | 68 (62.96) | 41 (49.39%) | 0.060 |
Anterior Synechiae | 13 (12.03%) | 4 (4.81%) | 0.082 |
Posterior Synechiae | 39 (36.11%) | 20 (24.09%) | 0.075 |
Trabeculitis | 8 (7.40%) | 5 (6.02%) | 0.707 |
Time topical steroids (weeks) | 9 (1.0–33.2) | 12.5 (4.0–61.9) | 0.186 |
Mean number of hypotensive agents | 3.0 (2.0–3.0) | 2.0 (1.0–3.0) | 0.003 |
Last Visit Cup/Disc ratio | 0.5 (0.3–0.8) | 0.2 (0.1–0.3) | <0.001 |
Highest IOP (IQR 25th and 75th) [Range] | 28 (18.0–35.7) [10–56] | 22.0 (18.0–28.0) [6–62] | 0.089 |
